Gri Bio, INC 8-K filings

GRI Bio has entered into agreements to exercise existing warrants at a reduced price, generating approximately $0.8 million in gross proceeds and issuing new warrants.

GRI Bio, Inc. received a notice from Nasdaq for failing to meet the minimum bid price requirement, triggering a potential delisting process.

GRI Bio has been notified by Nasdaq that it no longer meets the minimum bid price requirement, triggering a compliance period.

GRI Bio, Inc. successfully reconvened its 2024 Annual Meeting, electing a new director and approving proposals related to auditor ratification, warrant issuances, and an equity incentive plan amendment.

GRI Bio adjourned its 2024 Annual Meeting to September 6th to gather more proxies for pending proposals after failing to secure sufficient votes on August 23rd.

GRI Bio announced its Q2 2024 financial results, highlighting its focus on the Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis (IPF) and its intention to raise additional capital to support operations beyond Q1 2025.

GRI Bio has increased the maximum number of shares it can issue under its At The Market Offering Agreement to $2.6 million, excluding shares already sold.

GRI Bio has increased the maximum number of shares it can issue under its At-The-Market Offering Agreement to a total of $1,038,886.

GRI Bio has successfully regained compliance with Nasdaq listing standards, leading to the cancellation of a scheduled hearing.

GRI Bio, a biotechnology company, has announced the pricing of a $4 million public offering to support its pipeline of Natural Killer T cell modulators.

GRI Bio has amended its employment agreement with Chief Medical Officer Albert Agro, Ph.D., reducing his salary to $100,000, removing his bonus eligibility, and changing his work commitment to a minimum of 70 hours per month.

GRI Bio has announced a 1-for-13 reverse stock split of its common stock, effective June 17, 2024, to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

GRI Bio stockholders approved a reverse stock split proposal and a proposal to adjourn the special meeting if necessary to solicit additional proxies.

GRI Bio has received a delisting notice from Nasdaq due to not meeting the minimum stockholders' equity requirement, despite reporting over $2.5 million in equity, and plans to appeal the decision.

GRI Bio, Inc. has entered into an agreement with H.C. Wainwright & Co., LLC to potentially sell up to $961,579 of its common stock through an at-the-market offering.

GRI Bio announced its first quarter 2024 financial results and provided an update on its clinical programs, including upcoming milestones for its lead drug candidates.

GRI Bio reported its 2023 financial results, highlighted clinical progress for its lead programs, and announced a recent $5.5 million capital raise.

GRI Bio, a biotechnology company, has announced the pricing of a $5.5 million public offering to fund the development of its Natural Killer T (NKT) cell modulator pipeline.

GRI Bio has enacted a 1-for-7 reverse stock split to increase its share price and meet Nasdaq's minimum bid price requirement.

GRI Bio stockholders approved a reverse stock split proposal and a proposal to adjourn the special meeting if needed to secure more votes for the reverse stock split.

GRI Bio, Inc. released a corporate update highlighting progress in their NKT cell modulator pipeline for inflammatory, fibrotic, and autoimmune diseases, including upcoming clinical trial data.